Efficacy and safety of modified Xiao-Feng Powder in the treatment of chronic urticaria: protocol of a randomized double-blind placebo-controlled study.
Chinese medicine
Urticaria
Xiao-Feng Powder
Journal
Chinese medicine
ISSN: 1749-8546
Titre abrégé: Chin Med
Pays: England
ID NLM: 101265109
Informations de publication
Date de publication:
22 Jul 2022
22 Jul 2022
Historique:
received:
07
04
2022
accepted:
09
07
2022
entrez:
22
7
2022
pubmed:
23
7
2022
medline:
23
7
2022
Statut:
epublish
Résumé
Chronic Urticaria (CU), a common skin disorder known as Yin Zhen in Chinese medicine, is characterized by recurrent, pruritic, pink-to-red edematous lesions and wheals on the skin. Xiao-Feng Powder (XFP, meaning Wind-Dispersing Powder), is reported to be one of the most frequently used Chinese herbal formulae for CU. In this study, we aim to investigate the effectiveness and safety of modified Xiao-Feng Powder (mXFP) for the treatment of CU. In this randomised double-blind placebo-controlled clinical trial, 58 subjects identified as having mild to severe urticaria (Urticaria activity score greater than 10) will be recruited and randomised into two groups to receive antihistamine Bilastine with either mXFP or placebo for 12 weeks, followed by post treatment visits at week 16. The primary outcome measure is the change of weekly urticaria activity score (UAS7) at week 12. Secondary outcome measures include the Urticaria Control Test (UCT), Visual Analog Scale of Itch Severity (VAS), Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL), Angioedema Activity Score (AAS), immunoglobulin E (IgE) test, gut microbiota test and use of antihistamines during study period. The trial will be conducted at three Chinese medicine clinics in Hong Kong. The results of this study will establish robust clinical evidence about the efficacy and safety of mXFP in the treatment of CU. A specific feature of this trial is that it is a integrative medicine trial with subjects being allowed to take the Western and Chinese medicine together for the treatment. Trial registration This is registered on ClinicalTrials.gov, ID: NCT04967092. Register date: July 19, 2021. https://clinicaltrials.gov/ct2/show/NCT04967092 .
Sections du résumé
BACKGROUND
BACKGROUND
Chronic Urticaria (CU), a common skin disorder known as Yin Zhen in Chinese medicine, is characterized by recurrent, pruritic, pink-to-red edematous lesions and wheals on the skin. Xiao-Feng Powder (XFP, meaning Wind-Dispersing Powder), is reported to be one of the most frequently used Chinese herbal formulae for CU. In this study, we aim to investigate the effectiveness and safety of modified Xiao-Feng Powder (mXFP) for the treatment of CU.
METHODS
METHODS
In this randomised double-blind placebo-controlled clinical trial, 58 subjects identified as having mild to severe urticaria (Urticaria activity score greater than 10) will be recruited and randomised into two groups to receive antihistamine Bilastine with either mXFP or placebo for 12 weeks, followed by post treatment visits at week 16. The primary outcome measure is the change of weekly urticaria activity score (UAS7) at week 12. Secondary outcome measures include the Urticaria Control Test (UCT), Visual Analog Scale of Itch Severity (VAS), Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL), Angioedema Activity Score (AAS), immunoglobulin E (IgE) test, gut microbiota test and use of antihistamines during study period. The trial will be conducted at three Chinese medicine clinics in Hong Kong.
EXPECTED OUTCOMES
OBJECTIVE
The results of this study will establish robust clinical evidence about the efficacy and safety of mXFP in the treatment of CU. A specific feature of this trial is that it is a integrative medicine trial with subjects being allowed to take the Western and Chinese medicine together for the treatment. Trial registration This is registered on ClinicalTrials.gov, ID: NCT04967092. Register date: July 19, 2021. https://clinicaltrials.gov/ct2/show/NCT04967092 .
Identifiants
pubmed: 35869554
doi: 10.1186/s13020-022-00642-3
pii: 10.1186/s13020-022-00642-3
pmc: PMC9308295
doi:
Banques de données
ClinicalTrials.gov
['NCT04967092']
Types de publication
Journal Article
Langues
eng
Pagination
87Informations de copyright
© 2022. The Author(s).
Références
Medicine (Baltimore). 2018 Nov;97(45):e13039
pubmed: 30407300
Prim Care. 2008 Mar;35(1):141-57, vii-viii
pubmed: 18206722
Ann Allergy Asthma Immunol. 2012 Jan;108(1):20-24
pubmed: 22192960
Clin Dermatol. 2014 May-Jun;32(3):420-3
pubmed: 24767190
Clin Exp Allergy. 2015 Mar;45(3):547-65
pubmed: 25711134
J Ethnopharmacol. 2013 Jul 9;148(2):556-62
pubmed: 23684721
Int Arch Allergy Immunol. 2011;155(2):141-8
pubmed: 21196758
Allergy. 2011 Mar;66(3):317-30
pubmed: 21083565
Allergy Asthma Proc. 2015 Sep-Oct;36(5):394-8
pubmed: 26314821
Am Fam Physician. 2011 May 1;83(9):1078-84
pubmed: 21534521
Allergy. 2018 Jul;73(7):1393-1414
pubmed: 29336054
J Ethnopharmacol. 2015 Jun 20;168:260-7
pubmed: 25865681
J Allergy Clin Immunol. 2014 May;133(5):1270-7
pubmed: 24766875
Curr Allergy Asthma Rep. 2018 May 24;18(7):36
pubmed: 29796863
Complement Ther Med. 2009 Jan;17(1):29-36
pubmed: 19114226
BMC Complement Altern Med. 2013 Aug 15;13:209
pubmed: 23947955
Front Pharmacol. 2018 Dec 18;9:1474
pubmed: 30618764
Allergy. 2014 Jul;69(7):868-87
pubmed: 24785199
Pediatrics. 2012 Jun;129(6):e1485-92
pubmed: 22585761